New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Background The monoclonal antibody natalizumab (NAT) inhibits the migration of lymphocytes throughout the blood–brain barrier by blocking very late antigen (VLA)-4 interactions, thereby reducing inflammatory central nervous system (CNS) activity in patients with multiple sclerosis (MS). We evaluated...

Full description

Bibliographic Details
Main Authors: Sehr, Tony, Proschmann, Undine, Thomas, Katja, Marggraf, Michaela, Straube, Elmar, Reichmann, Heinz, Chan, Andrew, Ziemssen, Tjalf
Other Authors: Biomed Central,
Format: Article
Language:English
Published: Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden 2016
Subjects:
Multiple Sklerose
Therapieüberwachung
Tysabri
Natalizumab
CSF
Immunologie
TU Dresden
Publikationsfonds
Multiple sclerosis
Treatment monitoring
Immunology
Publicationfonds
ddc:610
rvk:XA 10000
Online Access:http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-213630
http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-213630
http://www.qucosa.de/fileadmin/data/qucosa/documents/21363/ziemssen.pdf

Internet

http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-213630
http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-213630
http://www.qucosa.de/fileadmin/data/qucosa/documents/21363/ziemssen.pdf

Similar Items